Cart
sales@molnova.com
Spesolimab
CAS No. 2097104-58-8
Spesolimab( —— )
Catalog No. M36760 CAS No. 2097104-58-8
Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1/Th17 and neutrophil pathways.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 705 | In Stock |
|
| 10MG | 1131 | In Stock |
|
| 25MG | 1682 | In Stock |
|
| 50MG | 2213 | In Stock |
|
| 100MG | 2995 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSpesolimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSpesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1/Th17 and neutrophil pathways.
-
DescriptionSpesolimab (BI 655130) is an anti-IL-36R antibody. IL-36 involves in immune system, as Spesolimab can be used for palmoplantar pustulosis (PPP) research. Spesolimab is associated with the reduction of biomarkers linked to innate, Th1/Th17, and neutrophilic pathways.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2097104-58-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mrowietz U, et al. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb). 2021 Apr;11(2):571-585.?
molnova catalog
related products
-
YM-90709
A potent IL-5 receptor antagonist that inhibits the binding of IL-5 to its receptor on peripheral human eosinophils and butyric acid-treated eosinophilic HL-60 clone 15 cells with IC50 of 1.0 and 0.57 uM, respectively.
-
MyD88-IN-1
MyD88-IN-1 is a potent MyD88 inhibitor with anti-inflammatory activity, inhibiting downstream pathways such as the NF-κB pathway of the Toll-like receptor (TLR) and interleukin-1 (IL-1) receptor family.
-
Kansuinine A
Kansuinine A, a 95% ethanol extract from the roots of E. kansui, possesses an inhibitory effect on IL-6-induced Stat3 activation by activating ERK1/2.
